Skip to main content
. 2024 Dec 5;131(1):e35678. doi: 10.1002/cncr.35678

TABLE 1.

Description of the study population.

No. of patients (%)
Set 1, n = 279 Set 2, n = 59
With progression Without progression p a With progression Without progression p a
Age, median [IQR], years 68 [61.0–73.5] 66 [60.0–72.0] 63.5 [60.8–69.3] 66 [56–73.5]
Follow‐up: Median [IQR], months 67.2 [35.5–105.4] 58.4 [31.4–87.6] 41.9 [18.5–85.4] 40.2 [13.8–80.7]
Sex .351 .197
Men 37 66 3 12
Women 53 123 17 27
BMI, kg/m2 .848 .815
<18.0 3 4 2 0
18.0–25.9 47 121 11 18
26.0–29.9 23 30 7 16
≥30 11 16 0 3
Not available 6 8 0 2
Smoking .899 .651
No, never 59 124 14 25
Yes 32 65 6 14
Alcohol consumption .606 .795
No, never 53 106 13 24
Yes 37 83 7 15
Type 2 diabetes .069 .080
No 75 172 15 36
Yes 15 17 5 3
Cyst size at diagnosis, mm 8.92e−06 .448
<15.0 36 126 10 21
15.1–29.9 54 63 10 18
Family history of pancreatic cancer .421 .198
No 79 172 19 32
Yes 11 17 1 7

Abbreviations: BMI, body mass index; IQR, interquartile range.

aThe p value of the variable distribution between the groups of patients with and without clinical progression.